Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Pharma-Bio Serv (PBSV) over the last 16 years, with Q4 2025 value amounting to 6.2%.

  • Pharma-Bio Serv's EBITDA Margin rose 4100.0% to 6.2% in Q4 2025 from the same period last year, while for Oct 2025 it was 7.08%, marking a year-over-year increase of 64600.0%. This contributed to the annual value of 7.08% for FY2025, which is 64600.0% up from last year.
  • According to the latest figures from Q4 2025, Pharma-Bio Serv's EBITDA Margin is 6.2%, which was up 4100.0% from 15.99% recorded in Q3 2025.
  • Pharma-Bio Serv's 5-year EBITDA Margin high stood at 10.06% for Q3 2023, and its period low was 85.72% during Q4 2021.
  • For the 5-year period, Pharma-Bio Serv's EBITDA Margin averaged around 5.06%, with its median value being 1.1% (2023).
  • In the last 5 years, Pharma-Bio Serv's EBITDA Margin tumbled by -887400bps in 2021 and then surged by 893600bps in 2022.
  • Quarter analysis of 5 years shows Pharma-Bio Serv's EBITDA Margin stood at 85.72% in 2021, then soared by 104bps to 3.64% in 2022, then crashed by -139bps to 1.44% in 2023, then tumbled by -359bps to 6.61% in 2024, then grew by 6bps to 6.2% in 2025.
  • Its EBITDA Margin stands at 6.2% for Q4 2025, versus 15.99% for Q3 2025 and 4.07% for Q2 2025.